Dahuang Zhechong Pill Combined with Doxorubicin Induces Cell Death through Regulating Energy Metabolism in Human Hepatocellular Carcinoma Cells.
Li WuJiayu ZhaoHao CaiJiaqi WangZhipeng ChenWei-Dong LiXiao LiuPublished in: Evidence-based complementary and alternative medicine : eCAM (2017)
Many physiological activities such as cell survival, proliferation, defense, adaptation, and metabolism need to consume energy. Hepatoma cells can quickly start stress responses like multidrug resistance (MDR) requiring adenosine triphosphate (ATP) consumption after administration of chemotherapeutics. We employed CCK-8 assay to evaluate cell viability and the flow cytometry to confirm apoptosis and necrosis. ELISA kit was used to determine intracellular levels of ATP in lysates. Western blot was employed to analyze the expressions of key enzymes involved in energy metabolism. We found that doxorubicin (DOX) potently stimulated apoptosis at a low dose and even induced necrosis at a high dose in SMMC-7721. DHZCP combined with DOX at low or middle dose enhanced the synergistic antihepatoma effect. Results indicated that Dahuang Zhechong Pill (DHZCP) inhibited the expressions of several key enzymes involved in oxidative phosphorylation and reduced intracellular ATP levels. The combination of DHZCP with DOX reversed the elevation of intracellular ATP levels, and a significantly synergistic antitumor effect was observed. DHZCP could not only strengthen the therapeutic effects of chemotherapeutic drugs but also decrease the doses of chemotherapeutic drugs and the incidences of adverse reactions, providing novel strategies for clinical treatment of liver cancer.
Keyphrases
- cell cycle arrest
- cell death
- low dose
- high dose
- flow cytometry
- cancer therapy
- oxidative stress
- endoplasmic reticulum stress
- pi k akt
- endothelial cells
- induced apoptosis
- drug delivery
- high glucose
- reactive oxygen species
- signaling pathway
- multidrug resistant
- drug induced
- stem cell transplantation
- protein kinase
- high throughput
- diabetic rats
- cell proliferation
- induced pluripotent stem cells